Frovatriptan-d₃ hydrochloride  (Synonyms: (R)-Frovatriptan-d₃ hydrochloride; SB 209509-d₃ hydrochloride; VML 251-d₃ hydrochloride)

Frovatriptan-d₃ (hydrochloride) is the deuterium labeled Frovatriptan[1]. Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura[2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

282.78

C₁₄H₁₅D₃ClN₃O

158747-02-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Stefan Evers, et al. Efficacy of frovatriptan as compared to other triptans in migraine with aura.